- Home
- GOOD vs SCTX Comparison
GOOD vs SCTX Comparison
Compare GOOD & SCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GOOD | SCTX |
|---|---|---|
| Founded | 2003 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 624.9M | 536.5M |
| IPO Year | 2003 | 2026 |
Fundamental Metrics
Financial Performance| Metric | GOOD | SCTX |
|---|---|---|
| Price | $12.02 | $15.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $14.13 | ★ $57.00 |
| AVG Volume (30 Days) | ★ 468.1K | 415.3K |
| Earning Date | 11-03-2026 | 11-29-2026 |
| Dividend Yield | ★ 10.00% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $161,336,000.00 | N/A |
| Revenue This Year | $5.94 | N/A |
| Revenue Next Year | $3.02 | N/A |
| P/E Ratio | $66.53 | ★ N/A |
| Revenue Growth | ★ 8.00 | N/A |
| 52 Week Low | $10.33 | $13.50 |
| 52 Week High | $13.28 | $39.60 |
Technical Indicators
Market Signals| Indicator | GOOD | SCTX |
|---|---|---|
| Relative Strength Index (RSI) | 38.69 | 33.52 |
| Support Level | $11.15 | $13.50 |
| Resistance Level | $13.07 | $22.07 |
| Average True Range (ATR) | 0.32 | 2.40 |
| MACD | -0.08 | -0.01 |
| Stochastic Oscillator | 28.98 | 2.88 |
Price Performance
Historical ComparisonAbout GOOD Gladstone Commercial Corporation Real Estate Investment Trust
Gladstone Commercial Corp is a real estate investment trust, which engages in investing and owning net leased industrial, commercial, and retail real property and making long-term industrial and commercial mortgage loans. Its portfolio consists of single-tenant commercial, industrial real properties, and medical properties nationwide. Its principal investment objectives are to generate income from rental properties.
About SCTX Scribe Therapeutics Inc. Common Stock
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.